William Blair Thinking
Cloud Computing: Dark Days, or Sunny Skies Ahead?
While gen AI continues to dominate the headlines, the once-ubiquitous “cloud” continues to face headwinds amid spending cuts. However, are the best days of cloud computing really behind us? Or, as equity analysts Jason Ader explains, select players within the cloud computing industry are—and remain—the future of IT.
Read moreSettling in for the Long Haul
Ken McAtamney, portfolio manager and head of William Blair Investment Management’s global equity team, shares his economic outlook for the remainder of the year.
Read moreCEO Perspective: Evaluating Mixed Signals for the Second Half of 2023
Brent Gledhill shares his thoughts on what investors may face heading into the last six months of the year.
Read moreOur Mission, Vision, and Values
At William Blair, we're committed to our colleagues, our clients, and our communities. Serving our clients starts with the capabilities and collaboration of our team—making our employees our most important asset. When we create an environment where employees perform their best, our delivery for clients will be the best it can be.
Learn more about our mission, vision, and values
Community Engagement at William Blair
"Our job is to bridge the gap between those students who live in underserved communities and the financial industry. What William Blair has done has fully bought into our model of getting to know these young people, understanding their background, and understanding what we are trying to achieve. If not for William Blair, we would not be where we are today.”
Bevon Joseph, Co-Founder of Greenwood Project
Our Latest News
TransMedics Group, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of TransMedics Group, Inc. (TMDX $94.04), the leading provider of organ care systems for end-stage organ failure patients across multiple disease states.
Read moreTarsus Pharmaceuticals, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Tarsus Pharmaceuticals, Inc. (TARS $17.65), a development-stage biopharmaceutical company focused on therapies that address large market opportunities in ophthalmic conditions with limited treatment options.
Read moreEconomics Weekly: Will Interest Rates Be Higher for Longer?
In this Economics Weekly, we discuss current views around the real neutral short-term interest rate, where it might be, and how it might or might not have changed since the pandemic and the war in Ukraine.
Read moreJoin Our Team
Finding, attracting, and developing talented people is the foundation of our success. Learn about the promising career opportunities currently available at William Blair.
Search for jobs and apply
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news








